Trans Genic Inc. (JP:2342)
:2342
2342 Stock Chart & Stats
¥254.00
-¥3.00(-1.68%)
At close: 4:00 PM EST
¥254.00
-¥3.00(-1.68%)
Day’s Range― - ―
52-Week Range¥130.00 - ¥487.00
Previous CloseN/A
Volume37.40K
Average Volume (3M)549.15K
Market Cap
¥4.50B
Enterprise Value¥5.14B
Total Cash (Recent Filing)¥2.30B
Total Debt (Recent Filing)¥2.85B
Price to Earnings (P/E)―
Beta1.04
Next Earnings
May 08, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.09
Shares Outstanding16,999,142
10 Day Avg. Volume1,508,680
30 Day Avg. Volume549,150
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.64
Price to Sales (P/S)0.23
P/FCF Ratio-37.42
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Balance Sheet StabilityModerate leverage and a stable equity base provide financial flexibility to fund R&D and model production over time. A steadier balance sheet reduces refinancing risk, allowing management to support long-term contracts and capital needs through cyclical research funding environments.
Improving Operating Cash FlowA recent positive shift in operating cash flow and a healthy operating cash flow to net income ratio indicate improving cash generation from core activities. Sustained operating cash inflows can fund day-to-day lab operations and reduce reliance on external financing over the medium term.
Niche Research Tools BusinessSpecialization in genetically engineered animal models gives the company a focused addressable market with high technical barriers and recurring demand from drug discovery labs. This niche positioning supports durable customer relationships and pricing power versus commoditized lab suppliers.
Bears Say
Declining Revenue And LossesSustained revenue declines and negative EBIT/net income erode reinvestment capacity and shareholder returns. Over months this reduces scale economics for model production, weakens margins, and constrains the firm's ability to invest in new model development or expand service offerings.
Negative Free Cash FlowPersistent negative free cash flow means the business cannot fully cover capex from operations, forcing reliance on external capital or debt. This limits capacity for strategic investment, raises financing risk, and can slow product development or capacity upgrades over a multi-month horizon.
Margin CompressionA sharply weaker gross margin suggests rising costs or pricing pressure in core products and services. If margins remain compressed, profitability recovery will be harder despite revenue stabilization, reducing cash available for R&D and weakening competitive resilience long-term.
2342 FAQ
What was Trans Genic Inc.’s price range in the past 12 months?
Trans Genic Inc. lowest stock price was ¥130.00 and its highest was ¥487.00 in the past 12 months.
What is Trans Genic Inc.’s market cap?
Trans Genic Inc.’s market cap is ¥4.50B.
When is Trans Genic Inc.’s upcoming earnings report date?
Trans Genic Inc.’s upcoming earnings report date is May 08, 2026 which is in 35 days.
How were Trans Genic Inc.’s earnings last quarter?
Trans Genic Inc. released its earnings results on Feb 10, 2026. The company reported -¥0.09 earnings per share for the quarter, missing the consensus estimate of N/A by -¥0.09.
Is Trans Genic Inc. overvalued?
According to Wall Street analysts Trans Genic Inc.’s price is currently Overvalued.
Does Trans Genic Inc. pay dividends?
Trans Genic Inc. pays a Annually dividend of ¥3 which represents an annual dividend yield of N/A. See more information on Trans Genic Inc. dividends here
What is Trans Genic Inc.’s EPS estimate?
Trans Genic Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Trans Genic Inc. have?
Trans Genic Inc. has 16,999,142 shares outstanding.
What happened to Trans Genic Inc.’s price movement after its last earnings report?
Trans Genic Inc. reported an EPS of -¥0.09 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 3.922%.
Which hedge fund is a major shareholder of Trans Genic Inc.?
Currently, no hedge funds are holding shares in JP:2342
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Trans Genic Inc.
Trans Genic Inc. develops, distributes, and licenses genetically modified animals and antibodies in Japan. It operates through Drug Discovery Support Business and Investment Business segments. The company provides glycan synthesis and analysis services; non-clinical studies for pharmaceuticals, foods, cosmetics, chemical substances, etc., as well as various safety tests for foods, and pharmaceutical agents; and support for bioequivalence test, including clinical trials, pharmacokinetic measurements, and the preparation of clinical trial reports; as well as hospital support services. It also offers drug efficiency and pharmacological test and safety studies; sugar chain analysis and synthesis services; advice and support services, including M&A, business revitalization, business succession services; and contract production services, such as genetically modified mice, antibodies, protein hypers, and expressing cells, as well as sells mouse-related products and mouse models, and research reagents. The company was formerly known as Kumamoto Immunochemical Laboratories Inc. and changed its name to Trans Genic Inc. in April 2000. Trans Genic Inc. was incorporated in 1998 and is headquartered in Fukuoka City, Japan.
Technical Analysis
CellSource Co., Ltd.
―
ReproCELL Inc.
―
PhoenixBio Co., Ltd.
―
Japan Tissue Engineering Co., Ltd.
―
CellSeed Inc.
―